These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18331547)

  • 1. What is the association between the tumor necrosis factor-alpha inhibitor infliximab and complex regional pain syndrome type I?
    Paraskevas KI
    Paediatr Anaesth; 2008 Jul; 18(7):689-90. PubMed ID: 18331547
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting oxidative injury and cytokines' activity in the treatment with anti-tumor necrosis factor-α antibody for complex regional pain syndrome 1.
    Miclescu AA; Nordquist L; Hysing EB; Butler S; Basu S; Lind AL; Gordh T
    Pain Pract; 2013 Nov; 13(8):641-8. PubMed ID: 23336526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab.
    Geissal ED; Wernick R
    J Clin Rheumatol; 2010 Jun; 16(4):185-7. PubMed ID: 20414125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.
    Mancini G; Erario L; Gianfreda R; Oliva A; Massetti AP; Mastroianni CM; Vullo V
    Clin Microbiol Infect; 2007 Oct; 13(10):1036-7. PubMed ID: 17711485
    [No Abstract]   [Full Text] [Related]  

  • 5. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis.
    Veerappan SG; Kennedy M; O'Morain CA; Ryan BM
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):588-9. PubMed ID: 18467922
    [No Abstract]   [Full Text] [Related]  

  • 6. Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease.
    Beccastrini E; Squatrito D; Emmi G; Fabbri P; Emmi L
    Dermatol Online J; 2010 Sep; 16(9):15. PubMed ID: 20875336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful intravenous regional block with low-dose tumor necrosis factor-alpha antibody infliximab for treatment of complex regional pain syndrome 1.
    Bernateck M; Rolke R; Birklein F; Treede RD; Fink M; Karst M
    Anesth Analg; 2007 Oct; 105(4):1148-51, table of contents. PubMed ID: 17898403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease.
    Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP
    J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 13. [TNF-blockade--new strategy in difficult-to-treat asthma].
    Dahlén SE; Millinger E; Skedinger M; Zetterström O; Dahlén B
    Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1946-8. PubMed ID: 18681378
    [No Abstract]   [Full Text] [Related]  

  • 14. [TNF blocker infliximab receives award. Quality leap in therapy of chronic inflammatory diseases].
    MMW Fortschr Med; 2009 Nov; 151(45):40-1. PubMed ID: 19960723
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab.
    Vega Gutierrez J; Rodriguez Prieto MA; Garcia Ruiz JM
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):570-1. PubMed ID: 17374009
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
    Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
    Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex regional pain syndrome in a HIV seropositive patient starting antiretroviral therapy.
    du Plessis CD; Aden AA; Firnhaber C; Sanne I
    J Clin Rheumatol; 2009 Oct; 15(7):371-2. PubMed ID: 20009979
    [No Abstract]   [Full Text] [Related]  

  • 18. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
    Evereklioglu C; Borlu M
    Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of mucous membrane pemphigoid with infliximab.
    Heffernan MP; Bentley DD
    Arch Dermatol; 2006 Oct; 142(10):1268-70. PubMed ID: 17043180
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis.
    Wilkinson NM; Erendzhinova E; Zeft A; Cabral DA
    Rheumatology (Oxford); 2006 Aug; 45(8):1047-8. PubMed ID: 16735453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.